GlassScriptPhysician profile
Mark A Wyse
NPI 1346200060
$17,130.48
in general payments reported to CMS, 2019-2025
68 companies · $2,202 in 2025
The $2,202 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,640 · 2020: $901 · 2021: $2,752 · 2022: $4,127 · 2023: $3,226 · 2024: $2,282 · 2025: $2,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,709.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,704.46 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $2,660.12 | 2020-2025 | Ubrelvy, Linzess, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,503.31 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $972.27 | 2021-2024 | Spravato |
| Glaxosmithkline, LLC. | $928.71 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $916.31 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $781.30 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Gilead Sciences, INC. | $690.45 | 2021-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $553.53 | 2019-2025 | Pifeltro, Dificid, Delstrigo |
| Abbott Laboratories | $535.09 | 2019-2025 | Freestyle Libre 3, Proclaim, Gallant |
| Pfizer INC. | $524.62 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $480.82 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $345.81 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $322.61 | 2019-2022 | |
| Lucid Diagnostics INC. | $293.87 | 2021-2022 |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wyse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.